Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coherus Bio (NQ: CHRS )

6.000 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,010
Open 6.000
Bid (Size) 5.800 (10)
Ask (Size) 6.680 (35)
Prev. Close 6.000
Today's Range 6.000 - 6.000
52wk Range 5.581 - 14.03
Shares Outstanding 79,609,789
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Coherus BioSciences's Return On Capital Employed Overview
 
Via Benzinga
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
From Coherus BioSciences, Inc.
Via Globe NewsWire

Performance

YTD
-29.49%
-29.49%
1 Month
-13.54%
-13.54%
3 Month
+5.45%
+5.45%
6 Month
-33.41%
-33.41%
1 Year
-49.87%
-49.87%

More News

Read More
FDA Approves UDENYCA® Autoinjector
From Coherus BioSciences, Inc.
Via Globe NewsWire
A Preview Of Coherus BioSciences's Earnings
Via Benzinga
Coherus BioSciences to Present at Upcoming Investor Conferences in March
From Coherus BioSciences, Inc.
Via Globe NewsWire
Looking Into Coherus BioSciences Return On Capital Employed
Via Benzinga
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
From Coherus BioSciences, Inc.
Via Globe NewsWire
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion
Via Talk Markets
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
From Coherus BioSciences, Inc.
Via Globe NewsWire
Coherus BioSciences Announces New Employment Inducement Grants
From Coherus BioSciences, Inc.
Via Globe NewsWire
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
From Coherus BioSciences, Inc.
Via Globe NewsWire
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
From Coherus BioSciences, Inc.
Via Globe NewsWire
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Coherus BioSciences, Inc.
Via Globe NewsWire
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Tesla, NIO And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Via Benzinga
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
From Junshi Biosciences
Via Globe NewsWire
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
From Coherus BioSciences, Inc.
Via Globe NewsWire
Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket
Via Benzinga
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Via Benzinga
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
From Coherus BioSciences, Inc.
Via Globe NewsWire
Coherus BioSciences Earnings Preview
Via Benzinga
Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
From Coherus BioSciences, Inc.
Via Globe NewsWire
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical
From Coherus BioSciences, Inc.; Shanghai Junshi Biosciences Co., Ltd
Via Globe NewsWire
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.